Valirx - A Company Reborn13 Aug 2024 07:59
Investing on AIM comes with its risks but also the potential for significant SP gains. Val now has a strong portfolio, top university tie-ups and an enviable scientific team working in state-of-the-art Inaphaea labs. A recent RNS confirmed potential contracts and we know at any time we could see an RNS confirming a motherlode with 401, CLX or even the toxic 201. More importantly, we have a management team of significant shareholders. They have as much incentive as any here to ensure the company is a success.
Mark, Adrian and Ray possess the business acumen and drive Val has always lacked, putting us in a stronger position than ever before. Few companies on AIM are managed by key SHs unless they have gained their shares thru’ free or discounted share awards. Our guys have paid full whack, just like normal hard-working Val shareholders.
In Martin Gouldstone, Val has a Chairman with 30 years experience in healthcare and pharma management. The recent appointment of Cathy as an Executive Director further strengthens the management team. Few AIM companies can boast such a strong line up. Previously Val had the science but didn’t know how to capitalise on its assets. Those days have gone.
Cash in the bank is the only unknown. That can change in an instant, One decent RNS and the cash runway is no longer an issue. Many, knowledgeable shareholders believe CLX001 to have the potential to propel Val into the big time. To get to that point we need to make the business viable and that will be the sole objective of the new management over the coming weeks and months.
Give our guys a chance to make their mark. The previous criticism of Val management having no skin in the game has been blown out of the water. Shareholders have achieved their objective with 3 key SHs in situ. Mark was only confirmed as CEO yesterday. Let’s give them the time to work their magic. I believe we might be pleasantly surprised.
Sign In
Follow the stocks
